CPK16

CPK16 is an experimental **small-molecule KCNT1 channel blocker** identified in a structure-based screening campaign aimed at finding alternatives to quinidine for **KCNT1 gain-of-function epilepsies**. In the cited preclinical study, CPK16 was one of five hit compounds that showed strong KCNT1-blocking activity in a fluorescence assay, and patch-clamp testing confirmed higher KCNT1-blocking potency than quinidine together with selectivity over hERG and Kv7.2 channels. Publicly available information in the provided source does not identify a sponsoring company, formal nonproprietary name, dosage form, or clinical development program specific to CPK16, so it is best characterized as an early **research-stage ion-channel modulator** being explored for severe drug-resistant epilepsies caused by KCNT1 hyperactivity.